These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26869171)

  • 1. Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients?
    Berezin A
    Diabetes Metab Syndr; 2016; 10(3):169-70. PubMed ID: 26869171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.
    Esteghamati A; Afarideh M; Feyzi S; Noshad S; Nakhjavani M
    Diabetes Metab Syndr; 2015; 9(4):258-65. PubMed ID: 25450818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between osteoprotegerin, fetuin-A, carotid intima media thickness, and urinary albumin excretion in Type 2 diabetes.
    Koluman BU; Mutluay R; Derici UB; Arinsoy T; Senlik Z; Bahar B; Sancak B; Oktan SO; Sindel S
    Clin Nephrol; 2013 Jul; 80(1):9-16. PubMed ID: 23458176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin, RANKL, ADMA, and Fetuin-A serum levels in children with type I diabetes mellitus.
    Chrysis D; Efthymiadou A; Mermigka A; Kritikou D; Spiliotis BE
    Pediatr Diabetes; 2017 Jun; 18(4):277-282. PubMed ID: 27028343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological role of fetuin A and its potential importance for prediction of cardiovascular risk in patients with type 2 diabetes mellitus].
    Horshuns'ka MIu; Karachentsev IuI; Kravchun NO; Ĭensen É; Leshchenko ZhA; Hladkykh OI; Krasova NS; Tyzhnenko TV; Opaleĭko IuA; Poltorak VV
    Ukr Biokhim Zh (1999); 2013; 85(3):10-21. PubMed ID: 23937044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
    Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
    Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of vascular calcification and mortality in patients with ESRD.
    Scialla JJ; Kao WH; Crainiceanu C; Sozio SM; Oberai PC; Shafi T; Coresh J; Powe NR; Plantinga LC; Jaar BG; Parekh RS
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):745-55. PubMed ID: 24458076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients.
    Lee JE; Kim HJ; Moon SJ; Nam JS; Kim JK; Kim SK; Yun GY; Ha SK; Park HC
    Korean J Intern Med; 2013 Nov; 28(6):668-77. PubMed ID: 24307842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcification biomarkers and vascular dysfunction in obesity and type 2 diabetes: influence of oral hypoglycemic agents.
    Schinzari F; Tesauro M; Bertoli A; Valentini A; Veneziani A; Campia U; Cardillo C
    Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E658-E666. PubMed ID: 31408377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients.
    Pateinakis P; Papagianni A; Douma S; Efstratiadis G; Memmos D
    BMC Nephrol; 2013 Jun; 14():122. PubMed ID: 23758931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The balance of fetuin-A and osteoprotegerin is independently associated with diastolic dysfunction in hemodialysis patients.
    Talib A; Nakagawa N; Saito E; Matsuki M; Kobayashi M; Akasaka K; Hirayama T; Ishida H; Sato N; Hasebe N
    Hypertens Res; 2012 Apr; 35(4):426-33. PubMed ID: 22129515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis.
    Noureldein MH; Abd El-Razek RS; El-Hefnawy MH; El-Mesallamy HO
    Diabetes Res Clin Pract; 2015 Sep; 109(3):513-20. PubMed ID: 26105582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy.
    Kadoglou NP; Kottas G; Lampropoulos S; Vitta I; Liapis CD
    Clin Drug Investig; 2014 Mar; 34(3):165-71. PubMed ID: 24307429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus.
    Barchetta I; Ceccarelli V; Cimini FA; Bertoccini L; Fraioli A; Alessandri C; Lenzi A; Baroni MG; Cavallo MG
    J Endocrinol Invest; 2019 May; 42(5):513-520. PubMed ID: 30132286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value of Osteoprotegerin for Detecting Coronary Artery Calcification in Type 2 Diabetes Mellitus Patients in Correlation with Extent of Calcification Detected by Multidetector Computed Tomography.
    Ahmed S; Sobh R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(6):845-851. PubMed ID: 30747085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients.
    Nybo M; Preil SR; Juhl HF; Olesen M; Yderstraede K; Gram J; Henriksen JE; Rasmussen LM
    Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):481-5. PubMed ID: 21726411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis.
    Shroff RC; Shah V; Hiorns MP; Schoppet M; Hofbauer LC; Hawa G; Schurgers LJ; Singhal A; Merryweather I; Brogan P; Shanahan C; Deanfield J; Rees L
    Nephrol Dial Transplant; 2008 Oct; 23(10):3263-71. PubMed ID: 18463323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function.
    Collado S; Coll E; Nicolau C; Azqueta M; Pons M; Cruzado JM; de la Torre B; Deulofeu R; Mojal S; Pascual J; Cases A
    BMC Nephrol; 2017 Sep; 18(1):290. PubMed ID: 28882110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes.
    Davenport C; Mahmood WA; Forde H; Ashley DT; Agha A; McDermott J; Sreenan S; Thompson CJ; McGrath F; McAdam B; Cummins PM; Smith D
    Eur J Endocrinol; 2015 Jul; 173(1):53-61. PubMed ID: 26036811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?
    Rozas Moreno P; Reyes García R; García-Martín A; Varsavsky M; García-Salcedo JA; Muñoz-Torres M
    J Endocrinol Invest; 2013 Jan; 36(1):16-20. PubMed ID: 22391059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.